<!DOCTYPE html><html lang="en" class="page"><head><meta charset="UTF-8"><meta name="viewport" content="width=device-width,initial-scale=1"><link rel="shortcut icon" href="favicon.ico" type="image/x-icon"><meta http-equiv="X-UA-Compatible" content="ie=edge"><meta name="theme-color" content="#111111"><title>Capnia bibliography</title><link rel="preload" href="fonts/WorkSansRegular.woff2" as="font" type="font/woff2" crossorigin><link rel="preload" href="fonts/WorkSansMedium.woff2" as="font" type="font/woff2" crossorigin><link rel="preload" href="fonts/WorkSansBold.woff2" as="font" type="font/woff2" crossorigin><link rel="preload" href="fonts/BarlowRegular.woff2" as="font" type="font/woff2" crossorigin><link rel="preload" href="fonts/BarlowBold.woff2" as="font" type="font/woff2" crossorigin><link rel="stylesheet" href="css/vendor.css"><link rel="stylesheet" href="css/main.css"><script defer="defer" src="js/main.js"></script></head><body class="page__body"><a class="skiplink" href="#main-bibliography">Go to main content</a><div class="site-container"><header class="header header--products"><div class="header__container container-additional"><a class="header__logo" href="index.html"><img src="./img/logo.svg" class="header__logo-image" width="176" height="40" alt="Capnia logo"></a><nav class="header__nav" aria-label="Main navigation" data-menu><ul class="header__nav-list"><li class="header__nav-item"><a class="header__nav-link header__nav-link--home" href="index.html">Home</a></li><li class="header__nav-item"><a class="header__nav-link" href="products.html"><i>CoSense <span>®</span> </i>Product</a></li><li class="header__nav-item header__nav-item--dropdown"><button class="header__nav-link js-btn-dropdown" type="button" aria-label="Open submenu navigation">Clinical Resources</button><div class="dropdown"><div class="dropdown__wrapper"><ul class="dropdown__list"><li class="dropdown__item"><a class="dropdown__link dropdown__link--studies" href="cosense-studies.html"><span class="dropdown__link-text"><i>CoSense <span>®</span> </i></span>Studies</a></li><li class="dropdown__item"><a class="dropdown__link" href="bibliography.html">Bibliography</a></li><li class="dropdown__item"><a class="dropdown__link" href="guidelines.html">Guidelines</a></li></ul></div></div></li><li class="header__nav-item"><a class="header__nav-link" href="about.html">About Us</a></li><li class="header__nav-item"><a class="header__nav-link header__nav-link--contact" href="#">Contact Us</a></li></ul></nav><button class="header__burger" aria-label="Open menu" aria-expanded="false" data-burger><span class="header__burger-line"></span></button></div></header><main class="page__main" id="main-bibliography"><section class="clinical-resources"><div class="container"><div class="clinical-resources__wrapper"><h1 class="clinical-resources__title title-huge">Clinical Resources</h1><ul class="clinical-resources__list"><li class="clinical-resources__item"><a class="clinical-resources__link" href="cosense-studies.html"><i>CoSense</i> Studies</a></li><li class="clinical-resources__item"><a class="clinical-resources__link clinical-resources__link--active" href="bibliography.html">Bibliography</a></li><li class="clinical-resources__item"><a class="clinical-resources__link" href="guidelines.html">Guidelines</a></li></ul><div class="clinical-resources__text text-huge"><p>Read the well-established and mounting body of evidence recognizing the risks of unmanaged Jaundice and supporting the use of ETCOc testing with newborns.</p></div></div></div></section><section class="clinical-resources-info" id="clinical-resources-info"><div class="clinical-resources-info__container container"><div class="clinical-resources-info__wrapper"><a class="clinical-resources-info__to-top" href="#clinical-resources-info">top</a><div class="clinical-resources-info__inner"><h2 class="clinical-resources-info__title">Bibliography</h2><ul class="clinical-resources-info__list"><li class="clinical-resources-info__item"><div class="clinical-resources-info__text text-medium"><p>Evidenced Based Studies Of <i>CoSense</i> ETCOc Monitoring</p></div><ul class="clinical-resources-info__sublist"><li class="clinical-resources-info__subitem"><div class="clinical-resources-info__accordion accordion js-accordion"><button class="accordion__control" type="button" aria-expanded="false"><span class="accordion__title text-medium">Feasibility of a non-invasive method to assess fetal hemolysis in utero during the third trimester. </span><span class="accordion__info text-medium">Bahr TM, Christensen TR, Cheatham LS, Page JM, and Christensen RD 2023 Journal of Perinatology; doi: 10.1038/s41372-023-01764-8 </span><span class="accordion__icon"></span></button><div class="accordion__content text-medium" aria-hidden="true"><p>A Single-centered unblinded randomized controlled trial of infants in the well-baby nursery to determine whether the use of ETCOc with transcutaneous bilirubin (TCB) can decrease the rate of first phototherapy within 7 days of life (DOL) and whether it is associated with early identification of infants who needed phototherapy. Trial size: 2,500 infants.</p><p>A Single-centered unblinded randomized controlled trial of infants in the well-baby nursery to determine whether the use of ETCOc with transcutaneous bilirubin (TCB) can decrease the rate of first phototherapy within 7 days of life (DOL) and whether it is associated with early identification of infants who needed phototherapy. Trial size: 2,500 infants.</p><ul><li>A Single-centered unblinded randomized controlled trial of infants in the well-baby nursery to determine whether the use of ETCOc with transcutaneous bilirubin (TCB) can decrease the rate of first phototherapy within 7 days of life (DOL) and whether it is associated with early identification of infants who needed phototherapy. Trial size: 2,500 infants.</li><li>The intervention group received risk assessment based on ETCOc: a&nbsp;level &lt; 1.5 ppm indicates low risk, a&nbsp;level &ge; 1.5 ppm indicates increased risk for hemolysis. Controls had empirical risk assessment by&nbsp;pediatricians per local practice with ETCOc masked.</li><li>The intervention was associated with decreased need of phototherapy in&nbsp;7&nbsp;DOL by&nbsp;23%.</li><li>The intervention group started phototherapy earlier with higher ETCOc level but similar TCB/TSB.</li><li>No acute bilirubin encephalopathy occurred.</li><li>Risk assessment by&nbsp;ETCOc (vs. empirical assessment per local practice) can decrease the rate of&nbsp;unnecessary phototherapy by&nbsp;23%.</li><li>ETCOc may be able to identify those who require phototherapy earlier.</li></ul><b>Focus of Guideline</b><p>A Single-centered <i>Pediatrics</i> unblinded randomized controlled trial of infants in the well-baby nursery to determine whether the use of ETCOc with transcutaneous bilirubin (TCB) can decrease the rate of first phototherapy within 7 days of life (DOL) and whether it is associated with early identification of infants who needed phototherapy. Trial size: 2,500 infants.</p></div></div></li><li class="clinical-resources-info__subitem"><div class="clinical-resources-info__accordion accordion js-accordion"><button class="accordion__control" type="button" aria-expanded="false"><span class="accordion__title text-medium">[2023 Poster] ETCOc Test: An Aid to identify Neonatal Hemolysis </span><span class="accordion__info text-medium">Ruparel JN, Madani A, Escovedo C, Henry A, Nadar K, Rabizadeh S, Bhutani V, Berger G, Reanton G, and Mirocha J.Cedars-Sinai Medical Center, Los Angeles, CA </span><span class="accordion__icon"></span></button><div class="accordion__content text-medium" aria-hidden="true"><p>A Single-centered unblinded randomized controlled trial of infants in the well-baby nursery to determine whether the use of ETCOc with transcutaneous bilirubin (TCB) can decrease the rate of first phototherapy within 7 days of life (DOL) and whether it is associated with early identification of infants who needed phototherapy. Trial size: 2,500 infants.</p><p>A Single-centered unblinded randomized controlled trial of infants in the well-baby nursery to determine whether the use of ETCOc with transcutaneous bilirubin (TCB) can decrease the rate of first phototherapy within 7 days of life (DOL) and whether it is associated with early identification of infants who needed phototherapy. Trial size: 2,500 infants.</p></div></div></li><li class="clinical-resources-info__subitem"><div class="clinical-resources-info__accordion accordion js-accordion open is-open"><button class="accordion__control" type="button" aria-expanded="false"><span class="accordion__title text-medium">Hyperbilirubinemia Risk Evaluation and Management by End-tidal Carbon Monoxide-corrected (ETCOc) in Near-term and Term Chinese Neonates: A Randomized Controlled Clinical Trial Identification of Neonatal Hemolysis in China </span><span class="accordion__info text-medium">Yang G, Deng L, Zhang K, Yuan Y, Zhang H. Pediatric Academic Societies (PAS) 2023 </span><span class="accordion__icon"></span></button><div class="accordion__content text-medium" aria-hidden="true"><ul><li>A Single-centered unblinded randomized controlled trial of infants in the well-baby nursery to determine whether the use of ETCOc with transcutaneous bilirubin (TCB) can decrease the rate of first phototherapy within 7 days of life (DOL) and whether it is associated with early identification of infants who needed phototherapy. Trial size: 2,500 infants.</li><li>The intervention group received risk assessment based on ETCOc: a&nbsp;level &lt; 1.5 ppm indicates low risk, a&nbsp;level &ge; 1.5 ppm indicates increased risk for hemolysis. Controls had empirical risk assessment by&nbsp;pediatricians per local practice with ETCOc masked.</li><li>The intervention was associated with decreased need of phototherapy in 7 DOL by 23%.</li><li>The intervention group started phototherapy earlier with higher ETCOc level but similar TCB/TSB.</li><li>No acute bilirubin encephalopathy occurred.</li><li>Risk assessment by ETCOc (vs. empirical assessment per local practice) can decrease the rate of unnecessary phototherapy by 23%.</li><li>ETCOc may be able to identify those who require phototherapy earlier.</li></ul></div></div></li><li class="clinical-resources-info__subitem"><div class="clinical-resources-info__accordion accordion js-accordion"><button class="accordion__control" type="button" aria-expanded="false"><span class="accordion__title text-medium">Identification of Neonatal Hemolysis in China</span> <span class="accordion__info text-medium">Du L. Pediatric Academic Societies (PAS) 2023</span> <span class="accordion__icon"></span></button><div class="accordion__content text-medium" aria-hidden="true"><p>A Single-centered unblinded randomized controlled trial of infants in the well-baby nursery to determine whether the use of ETCOc with transcutaneous bilirubin (TCB) can decrease the rate of first phototherapy within 7 days of life (DOL) and whether it is associated with early identification of infants who needed phototherapy. Trial size: 2,500 infants.</p><p>A Single-centered unblinded randomized controlled trial of infants in the well-baby nursery to determine whether the use of ETCOc with transcutaneous bilirubin (TCB) can decrease the rate of first phototherapy within 7 days of life (DOL) and whether it is associated with early identification of infants who needed phototherapy. Trial size: 2,500 infants.</p></div></div></li></ul></li><li class="clinical-resources-info__item"><div class="clinical-resources-info__text text-medium"><p>ETCOc Testing</p></div><ul class="clinical-resources-info__sublist"><li class="clinical-resources-info__subitem"><div class="clinical-resources-info__accordion accordion js-accordion"><button class="accordion__control" type="button" aria-expanded="false"><span class="accordion__title text-medium">End-tidal carbon monoxide is predictive for neonatal non-hemolytic hyperbilirubinemia. </span><span class="accordion__info text-medium">Okuyama H, Yonetani M, Uetani Y, Nakamura H. <i>Pediatr</i> Int. 2001 Aug;43(4):329-33. doi: 10.1046/j.1442-200x.2001.01412.x. </span><span class="accordion__icon"></span></button><div class="accordion__content text-medium" aria-hidden="true"><p>A Single-centered unblinded randomized controlled trial of infants in the well-baby nursery to determine whether the use of ETCOc with transcutaneous bilirubin (TCB) can decrease the rate of first phototherapy within 7 days of life (DOL) and whether it is associated with early identification of infants who needed phototherapy. Trial size: 2,500 infants.</p><p>A Single-centered unblinded randomized controlled trial of infants in the well-baby nursery to determine whether the use of ETCOc with transcutaneous bilirubin (TCB) can decrease the rate of first phototherapy within 7 days of life (DOL) and whether it is associated with early identification of infants who needed phototherapy. Trial size: 2,500 infants.</p><ul><li>A Single-centered unblinded randomized controlled trial of infants in the well-baby nursery to determine whether the use of ETCOc with transcutaneous bilirubin (TCB) can decrease the rate of first phototherapy within 7 days of life (DOL) and whether it is associated with early identification of infants who needed phototherapy. Trial size: 2,500 infants.</li><li>The intervention group received risk assessment based on ETCOc: a&nbsp;level &lt; 1.5 ppm indicates low risk, a&nbsp;level &ge; 1.5 ppm indicates increased risk for hemolysis. Controls had empirical risk assessment by&nbsp;pediatricians per local practice with ETCOc masked.</li><li>The intervention was associated with decreased need of phototherapy in 7 DOL by 23%.</li><li>The intervention group started phototherapy earlier with higher ETCOc level but similar TCB/TSB.</li><li>No acute bilirubin encephalopathy occurred.</li><li>Risk assessment by ETCOc (vs. empirical assessment per local practice) can decrease the rate of unnecessary phototherapy by 23%.</li><li>ETCOc may be able to identify those who require phototherapy earlier.</li></ul><b>Focus of Guideline</b><p>A Single-centered <i>Pediatrics</i> unblinded randomized controlled trial of infants in the well-baby nursery to determine whether the use of ETCOc with transcutaneous bilirubin (TCB) can decrease the rate of first phototherapy within 7 days of life (DOL) and whether it is associated with early identification of infants who needed phototherapy. Trial size: 2,500 infants.</p></div></div></li></ul></li><li class="clinical-resources-info__item"><div class="clinical-resources-info__text text-medium"><p>Hemolysis and Risk</p></div><ul class="clinical-resources-info__sublist"><li class="clinical-resources-info__subitem"><div class="clinical-resources-info__accordion accordion js-accordion"><button class="accordion__control" type="button" aria-expanded="false"><span class="accordion__title text-medium">Risk factors for readmission for phototherapy due to jaundice in healthy newborns: a retrospective, observational study. </span><span class="accordion__info text-medium">Blumovich A, Mangel L, Yochpaz S, Mandel D, Marom R. <i>BMC Pediatr.</i> 2020 May 26;20(1):248. doi: 10.1186/s12887-020-02157-y. </span><span class="accordion__icon"></span></button><div class="accordion__content text-medium" aria-hidden="true"><p>A Single-centered unblinded randomized controlled trial of infants in the well-baby nursery to determine whether the use of ETCOc with transcutaneous bilirubin (TCB) can decrease the rate of first phototherapy within 7 days of life (DOL) and whether it is associated with early identification of infants who needed phototherapy. Trial size: 2,500 infants.</p></div></div></li><li class="clinical-resources-info__subitem"><div class="clinical-resources-info__accordion accordion js-accordion"><button class="accordion__control" type="button" aria-expanded="false"><span class="accordion__title text-medium">Neonatal hyperbilirubinaemia: a global perspective. </span><span class="accordion__info text-medium">Olusanya BO, Kaplan M, Hansen TWR. <i>Lancet Child Adolesc Health.</i> 2018 Aug;2(8):610-620. doi: 10.1016/S2352-4642(18)30139-1. </span><span class="accordion__icon"></span></button><div class="accordion__content text-medium" aria-hidden="true"><p>A Single-centered unblinded randomized controlled trial of infants in the well-baby nursery to determine whether the use of ETCOc with transcutaneous bilirubin (TCB) can decrease the rate of first phototherapy within 7 days of life (DOL) and whether it is associated with early identification of infants who needed phototherapy. Trial size: 2,500 infants.</p></div></div></li></ul></li></ul></div></div></div></section></main><footer class="footer"><div class="footer__container container"><div class="footer__logo"><a class="footer__logo-link" href="index.html"><img class="footer__logo-image" src="./img/logo-footer.svg" width="174" height="39" alt="Capnia logo"></a></div><div class="footer__wrapper"><div class="footer__customer"><ul class="footer__social"><li class="footer__social-item"><a class="footer__social-link footer-link" href="privacy-statement.html">Customer Support</a></li><li class="footer__social-item"><a class="footer__social-link footer__social-link--careers footer-link" href="https://www.linkedin.com/company/capnia-inc./jobs/" target="_blank">Careers</a></li><li class="footer__social-item"><a class="footer__social-link footer__social-link--follow footer-link" href="https://www.linkedin.com/company/capnia-inc./about/" target="_blank">Follow Us</a></li><li class="footer__social-item"><a class="footer__social-link bilitool footer-link" href="https://bilitool.org" target="_blank" aria-label="link to Hyperbilirubinemia Guidelines"></a></li></ul></div><div class="footer__contact"><a class="footer__contact-link footer-link" href="#">Contact Us</a><address class="footer__contact-address footer-contact-item footer-contact-item--address">1101 Chess Drive Foster City, CA 94404</address><a class="footer__contact-tel footer-contact-item footer-contact-item--tel" href="tel:8664323788"><span class="footer__contact-text">Tel:</span> <span class="footer__contact-descr">(866) 432-3788</span> </a><a class="footer__contact-email footer-contact-item footer-contact-item--email" href="mailto:info@capnia.com"><span class="footer__contact-text">Email:</span> <span class="footer__contact-descr footer__contact-descr--email">info@capnia.com</span></a></div><a class="bilitool bilitool--mobile" href="https://bilitool.org" target="_blank" aria-label="link to Hyperbilirubinemia Guidelines"></a></div><div class="footer__info"><div class="footer__info-content"><span class="footer__info-item">CAPNIA, Inc. © 2024</span> <span class="footer__info-item">All Rights Reserved</span></div><div class="footer__info-content"><a class="footer__info-item" href="terms-of-use.html">Terms of Use</a> <a class="footer__info-item" href="privacy-statement.html">Privacy Statement</a></div></div></div></footer></div></body></html>